Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 9 de 9
Filter
1.
Inflammation ; 46(3): 861-875, 2023 Jun.
Article in English | MEDLINE | ID: mdl-36645607

ABSTRACT

B cell activating factor (BAFF) has been shown to play a key role in regulating B cell function, but little is known about whether BAFF affects the function of fibroblast-like synoviocyte (FLS), an effector cell of rheumatoid arthritis (RA). CP-25, a new ester derivative of paeoniflorin, could alleviate the arthritis symptoms of collagen-induced arthritis (CIA) mice by inhibiting BAFF-mediated abnormal activation of B cells. In this study, we aimed to understand the mechanism by which BAFF activates FLS and the effect of CP-25 on FLS function. Therefore, the proliferation and migration abilities of FLS and key proteins on the non-canonical NF-κB pathway were examined. The results showed that compared with the FLS of normal rats/OA patients, the expression of BAFF-R, TRAF2, NIK, p-IKKα, P100, and P52 was higher in the FLS of AA rats/RA patients, while the expression of TRAF3 was lower. And, BAFF promotes FLS activation by activating the non-canonical NF-κB signaling pathway. Meanwhile, BAFFR-siRNA inhibited the proliferation of FLS and the activation of non-canonical NF-κB signaling in FLS induced by BAFF. Additionally, CP-25 could inhibit abnormal proliferation and migration of FLS by regulating non-canonical NF-κB signaling. We concluded that BAFF may act as an important role in facilitating the function of FLS through the BAFFR-mediated non-canonical NF-κB pathway, which would be useful for revealing the pathological mechanism of RA. And CP-25 may become a potential new drug for the treatment of RA, providing a scientific basis for the development of new drugs to treat RA.


Subject(s)
Arthritis, Rheumatoid , Synoviocytes , Rats , Animals , Mice , NF-kappa B/metabolism , Synoviocytes/metabolism , B-Cell Activating Factor/metabolism , B-Cell Activating Factor/pharmacology , B-Cell Activating Factor/therapeutic use , Signal Transduction , Arthritis, Rheumatoid/metabolism , Fibroblasts/metabolism , Cell Proliferation , Synovial Membrane/metabolism , Cells, Cultured
2.
Inflammation ; 44(2): 746-757, 2021 Apr.
Article in English | MEDLINE | ID: mdl-33141376

ABSTRACT

This study aimed to investigate the effect of splenectomy on dexmedetomidine-activated cholinergic anti-inflammatory pathway-mediated alleviation of LPS-induced AKI. A mouse model of septic kidney injury was established in C57BL/6 mice. A total of 30 C57BL/6 mice were randomly divided into the control group, LPS group, dexmedetomidine + LPS group, splenectomy group, splenectomy + LPS group, and splenectomy + dexmedetomidine + LPS group. The pathological effects in kidney tissues in each group were analyzed by HE staining. Apoptosis in each group was examined by the TUNEL method. Cr and Cys-C levels in each group were measured by ELISA. The expression levels of IL-6, NF-κB p65, Caspase-3, the antiapoptotic protein Bcl-2, the proapoptotic protein Bax, and α7nAChR in each group were measured by qRT-PCR and Western blotting. Dexmedetomidine alone reduced apoptosis in kidney tissue; however, apoptosis was increased after splenectomy in mice treated with dexmedetomidine. Splenectomy reduced the production of proinflammatory cytokines in circulation and had a protective effect on the kidney. Splenectomy inhibited dexmedetomidine-mediated activation of the α7nAChR pathway. Dexmedetomidine effectively alleviated LPS-induced kidney injury, and splenectomy inhibited the anti-inflammatory, antiapoptotic, and renoprotective effects of dexmedetomidine. The kidney-spleen axis is mediated by the α7nAChR-NF-κB signaling pathway and is involved in the development of AKI.


Subject(s)
Acute Kidney Injury/immunology , Kidney/immunology , NF-kappa B/immunology , Spleen/immunology , alpha7 Nicotinic Acetylcholine Receptor/immunology , Acute Kidney Injury/drug therapy , Acute Kidney Injury/etiology , Acute Kidney Injury/metabolism , Animals , Anti-Inflammatory Agents/pharmacology , Anti-Inflammatory Agents/therapeutic use , Apoptosis/drug effects , Apoptosis/immunology , Biomarkers/metabolism , Blotting, Western , Dexmedetomidine/pharmacology , Dexmedetomidine/therapeutic use , Enzyme-Linked Immunosorbent Assay , In Situ Nick-End Labeling , Kidney/drug effects , Kidney/metabolism , Lipopolysaccharides , Male , Mice , Mice, Inbred C57BL , NF-kappa B/metabolism , Random Allocation , Sepsis/complications , Sepsis/immunology , Sepsis/metabolism , Signal Transduction/drug effects , Signal Transduction/immunology , Spleen/drug effects , Spleen/metabolism , Spleen/surgery , Splenectomy , alpha7 Nicotinic Acetylcholine Receptor/metabolism
3.
Medicine (Baltimore) ; 99(47): e23413, 2020 Nov 20.
Article in English | MEDLINE | ID: mdl-33217887

ABSTRACT

This study aims to explore effect of initiation of renal replacement therapy (RRT) on mortality in acute pancreatitis (AP) patients. In this study, a total of 92 patients from the surgical intensive care unit (SICU) of the Second Affiliated Hospital of Harbin Medical University who were diagnosed with AP and underwent RRT or not between January 2014 and December 2018 were included in this retrospective study. Demographic and clinical data were obtained on admission to SICU. Patients were divided into early initiation of RRT group (n = 44) and delayed initiation of RRT group (n = 48). Duration of mechanical ventilation (MV), intra-peritoneal pressure, vasopressors infusion, body temperature, procalcitonin, creatinine, platelet counts, length of hospital stay and prognosis were recorded during hospitalization, and then compared between groups. Patients with delayed initiation of RRT exhibited significantly higher APACHE II score, SOFA score and lower GCS score than those with early initiation of RRT (P < 0.001, <0.001,  = 0.04, respectively). No difference in the rest of the baseline data and vasopressors infusion was found. Dose of Norepinephrine, maximum and mean PCT, maximum and mean creatinine, maximum and mean intra-peritoneal pressure, length of hospital stay, prognosis of ICU and hospitalization showed significant difference between groups. Early initiation of RRT may be beneficial for AP patients, which can provide some insight and support for patients' treatment in clinic.


Subject(s)
Pancreatitis/mortality , Pancreatitis/therapy , Renal Replacement Therapy , APACHE , Adult , Biomarkers/blood , China , Female , Glasgow Coma Scale , Humans , Length of Stay/statistics & numerical data , Male , Middle Aged , Organ Dysfunction Scores , Prognosis , Retrospective Studies
4.
Biomed Res Int ; 2019: 9786101, 2019.
Article in English | MEDLINE | ID: mdl-31080837

ABSTRACT

Cardiac dysfunction is a major component of sepsis-induced multiorgan failure in critical care units. Uncoupling protein 2 (UCP2) involves immune response, regulation of oxidative stress, and maintenance of mitochondrial membrane potential as well as energy production. However, whether and how UCP2 plays roles in the development of septic cardiac dysfunction are largely unknown. Here, intraperitoneal injection of LPS significantly activated UCP2 expression accompanied by a significant decrease of cardiac function and caused a significantly lower survival rate in mice. Of note, knockdown of UCP2 through a cardiotropic adenoassociated viral vector carrying a short hairpin RNA (shRNA) specifically targeting the UCP2 evoked resistance to LPS-triggered septic cardiac dysfunction and lethality in vivo. Moreover, UCP2 deficiency ameliorated the reduced levels of intracellular ATP in the LPS-challenged heart tissues and preserved mitochondrial membrane potential loss in primary adult mouse cardiomyocytes in LPS-challenged animals. Mechanistically, we confirmed that the inhibition of UCP2 promoted autophagy in response to LPS, as shown by an increase in LC3II and a decrease in p62. At last, the autophagy inhibitor 3-MA abolished UCP2 knockdown-afforded cardioprotective effects. Those results indicate that UCP2 drives septic cardiac dysfunction and that the targeted induction of UCP2-mediated autophagy may have important therapeutic potential.


Subject(s)
Cardiomyopathies/metabolism , Shock, Septic/metabolism , Uncoupling Protein 2/immunology , Uncoupling Protein 2/metabolism , Adenosine Triphosphate/metabolism , Animals , Autophagy/drug effects , Gene Knockdown Techniques , Lipopolysaccharides/adverse effects , Male , Mice , Microtubule-Associated Proteins/metabolism , Mitochondria, Heart/drug effects , Mitochondrial Proteins/metabolism , Models, Animal , Myocytes, Cardiac/drug effects , Myocytes, Cardiac/metabolism , Oxidative Stress , RNA, Small Interfering , Reactive Oxygen Species/metabolism , Sepsis/metabolism , Survival Rate , Transcription Factor TFIIH , Transcription Factors , Uncoupling Protein 2/genetics
5.
Chin Med J (Engl) ; 132(10): 1208-1211, 2019 May 20.
Article in English | MEDLINE | ID: mdl-30882465

ABSTRACT

BACKGROUND: Blood purification (BP) is one of the most important rescue measures for patients with critical illness in the intensive care unit (ICU), especially for those with acute kidney injury. The purpose of this nationwide survey was to reveal the real world of current BP practice in different ICUs all over China. This study was designed to be a multi-center cross-sectional study. METHODS: All adult patients (over 18 years of age), who were admitted to ICU and required BP in 35 sub-centers across China were included during 30-day survey period in 2018. Demographic characteristics and clinical data were recorded including the timing of treatment initiation, indications, modality, relative contraindication, establishment of vascular access, selection of filter/membrane, settings, anti-coagulation, executive department, complication, intake, and output. DISCUSSION: This nationwide survey may contribute to reveal the real world of current BP practice in different ICUs all over China. TRIAL REGISTRATION: Chinese Clinical Trial Registry, ChiCTR-EOC-17013119; http://www.chictr.org.cn/showproj.aspx?proj=22487.


Subject(s)
Hemofiltration/methods , China , Cross-Sectional Studies , Humans , Intensive Care Units/statistics & numerical data , Models, Theoretical
6.
Biomed Pharmacother ; 106: 210-216, 2018 Oct.
Article in English | MEDLINE | ID: mdl-29960167

ABSTRACT

Acute kidney injury (AKI) is a clinical syndrome that results in severe tubular damage with high morbidity and mortality. However, there is a lack of effective therapy strategies. Therefore, it is critical to develop effective drugs for AKI. Dexmedetomidine (DEX), a highly selective α2-adrenoreceptor agonist, has neuroprotective, anti-inflammatory and sympatholytic properties. The present study aimed to investigate the effect DEX on attenuating the inflammatory reaction and apoptosis in the kidney tissues of septic mice and to explore its underlying mechanisms. Sepsis-induced AKI mice models were generated via intraperitoneal injection of lipopolysaccaride (LPS). DEX reduced LPS-induced local inflammation and tubular apoptosis, which was aggravated in the pathogenesis of renal dysfunction. Reverse transcription-quantitative polymerase chain reaction and western blot analysis results revealed that the expression of pro-apoptotic genes and inflammatory factors were markedly reduced by DEX pretreatment. Furthermore, the protective role of DEX was markedly inhibited by the α7 nicotinic acetylcholine receptor (nAChR) antagonist α-bungarotoxin. These findings provided novel evidence for the anti-apoptotic and anti-inflammatory effects of DEX in LPS-induced AKI mice through an α7 nAChR-dependent signaling pathway.


Subject(s)
Acute Kidney Injury/prevention & control , Anti-Inflammatory Agents/pharmacology , Apoptosis/drug effects , Dexmedetomidine/pharmacology , Kidney Tubules/drug effects , Lipopolysaccharides , Sepsis/drug therapy , alpha7 Nicotinic Acetylcholine Receptor/metabolism , Acute Kidney Injury/chemically induced , Acute Kidney Injury/metabolism , Acute Kidney Injury/pathology , Animals , Apoptosis Regulatory Proteins/genetics , Apoptosis Regulatory Proteins/metabolism , Cytoprotection , Disease Models, Animal , Inflammation Mediators/metabolism , Kidney Tubules/metabolism , Kidney Tubules/pathology , Male , Mice, Inbred C57BL , Sepsis/chemically induced , Sepsis/metabolism , Signal Transduction/drug effects , Time Factors
7.
Nan Fang Yi Ke Da Xue Xue Bao ; 37(11): 1545-1550, 2017 Nov 20.
Article in Chinese | MEDLINE | ID: mdl-29180339

ABSTRACT

OBJECTIVE: To observe the effects of deguelin on the proliferation of breast cancer MCF-7 cells and lung cancer H1299 cells in vitro and the expression of minichromosome maintenance protein 3 (MCM3) and CDC45 in the cells. METHODS: MTT assay was used to evaluate the proliferation of MCF-7 and H1299 cells exposed to different concentrations of deguelin for 48, 72 or 96 h. The growth of the cells was observed microscopically and the changes of MCM3 and CDC45 expressions in MCF-7 and H1299 cells following deguelin treatment were detected with fluorescence quantitative PCR. RESULTS: The proliferation of MCF-7 cells was significantly inhibited by exposure to 0.25, 0.5, 1, 5, 10, 30, and 50 µmol/L deguelin for 48, 72, and 96 h in a concentration- and time-dependent manner. In MCF-7 cells, the IC50 of deguelin at 48, 72, and 96 h was 9, 3, and 2 µmol/L, respectively. Deguelin treatments of H1299 cells at 0.5, 1, 5, 10, 30, 50, and 100 µmol/L also resulted in a concentration- and time-dependent inhibition of the cell growth with an IC50 at 96 h of 2 µmol/L. Optical microscopy of the cells revealed a decreased number of viable cells with obvious cell shrinkage following deguelin treatments. The expression of MCM3 and CDC45 were significantly reduced in the cells after deguelin treatments. CONCLUSION: Deguelin can inhibit the proliferation of MCF-7 and H1299 cells in vitro and down-regulate the expression of MCM3 and CDC45 in the cells.


Subject(s)
Cell Proliferation/drug effects , Rotenone/analogs & derivatives , Apoptosis , Cell Cycle , Cell Cycle Proteins , Cell Line, Tumor , Gene Expression Regulation, Neoplastic/drug effects , Humans , MCF-7 Cells , Minichromosome Maintenance Complex Component 3 , Rotenone/pharmacology
8.
World J Gastroenterol ; 23(24): 4422-4427, 2017 Jun 28.
Article in English | MEDLINE | ID: mdl-28706425

ABSTRACT

AIM: To assess the accuracy of serum procalcitionin (PCT) as a diagnostic marker in verifying upper and lower gastrointestinal perforation (GIP). METHODS: This retrospective study included 46 patients from the surgical intensive care unit (ICU) of the Second Affiliated Hospital of Harbin Medical University who were confirmed to have GIP between June 2013 and December 2016. Demographic and clinical patient data were recorded on admission to ICU. Patients were divided into upper (n = 19) and lower (n = 27) GIP groups according to the perforation site (above or below Treitz ligament). PCT and WBC count was obtained before laparotomy and then compared between groups. Meanwhile, the diagnostic accuracy of PCT was analyzed. RESULTS: Patients with lower GIP exhibited significantly higher APACHE II score, SOFA score and serum PCT level than patients with upper GIP (P = 0.017, 0.004, and 0.001, respectively). There was a significant positive correlation between serum PCT level and APACHE II score or SOFA score (r = 0.715 and r = 0.611, respectively), while there was a significant negative correlation between serum PCT level and prognosis (r = -0.414). WBC count was not significantly different between the two groups, and WBC count showed no significant correlation with serum PCT level, APACHE II score, SOFA score or prognosis. The area under the receiver operating characteristic curve of PCT level to distinguish upper or lower GIP was 0.778. Patients with a serum PCT level above 17.94 ng/dL had a high likelihood of lower GIP, with a sensitivity of 100% and a specificity of 42.1%. CONCLUSION: Serum PCT level is a reliable and accurate diagnostic marker in identifying upper or lower GIP before laparotomy.


Subject(s)
Calcitonin/blood , Intestinal Perforation/blood , Protein Precursors/blood , Sepsis/blood , APACHE , Aged , Bacterial Load , Biomarkers/analysis , Female , Humans , Intestinal Perforation/complications , Intestinal Perforation/diagnosis , Laparotomy , Leukocyte Count , Male , Middle Aged , Prognosis , Retrospective Studies , Sensitivity and Specificity , Sepsis/diagnosis , Sepsis/etiology , Sepsis/microbiology
9.
Pharmacol Res Perspect ; 4(2): e00212, 2016 04.
Article in English | MEDLINE | ID: mdl-27069628

ABSTRACT

Deguelin, a natural component derived from leguminous plants, has been used as pesticide in some regions. Accumulating evidence show that deguelin has promising chemopreventive and therapeutic activities against cancer cells. This study shows that low concentrations of deguelin can lead to significant delay in zebrafish embryonic development through growth inhibition and induction of apoptosis. Furthermore, we identified fibroblast growth factor receptor 4 (FGFR4) as the putative target of deguelin. The candidate was initially identified by a microarray approach and then validated through in vitro experiments using hormone-responsive (MCF-7) and nonresponsive (MDA-MB-231) human breast cancer cell lines. The results show that deguelin suppressed cell proliferation and induced apoptosis in both cancer cell lines, but not in Hs 578Bst cells, by blocking PI3K/AKT and mitogen-activated protein kinases (MAPK) signaling. The FGFR4 mRNA and protein level also diminished in a dose-dependent manner. Interestingly, we found that forced FGFR4 overexpression attenuated deguelin-induced proliferative suppression and apoptotic cell death in both zebrafish and MCF-7 cell lines, p-AKT and p-ERK levels were restored upon FGFR4 overexpression. Taken together, our results strongly suggest that deguelin inhibition of PI3K/AKT and MAPK signaling in zebrafish and breast cancer cell lines is partially mediated through down-regulation of FGFR4 activity.

SELECTION OF CITATIONS
SEARCH DETAIL
...